Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats

Molecular Carcinogenesis

Volumn 24, Issue 4, 1999, Pages 287-293

  Takahama, Makoto ^a   Tsutsumi, Masahiro ^a   Tsujiuchi, Toshifumi ^a   Kido, Akira ^a   Sakitani, Hiroyuki ^a   Iki, Katsumichi ^a   Taniguchi, Shigeki ^a   Kitamura, Soichiro ^b   Konishi, Yoichi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

N nitrosobis(2 hydroxypropyl)amine; Rat lung carcinogenesis; Vascular endothelial growth factor; Vascular endothelial growth factor receptors

Indexed keywords

BIS(2 HYDROXYPROPYL)NITROSAMINE; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADENOCARCINOMA; ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DISEASE MARKER; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; MALE; NONHUMAN; NORTHERN BLOTTING; PRECANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADENOMA; ANIMALS; BLOTTING, NORTHERN; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HYPERPLASIA; LUNG DISEASES; LUNG NEOPLASMS; LYMPHOKINES; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NITROSAMINES; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PULMONARY ALVEOLI; RATS; RATS, WISTAR; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032947564     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199904)24:4<287::AID-MC6>3.0.CO;2-T     Document Type: Article

References (61)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-473.
2. Le Querrec A, Duval D, Tobelem G. Tumor angiogenesis. Baillieres Clin Haematol 1993;6:711-730.
3. Liotta L, Kleinerman J, Saldel G. Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34: 997-1004.
4. Klagsbrun M, D'Amore PA. Regulation of angiogenesis. Annu Rev Physiol 1991;53:217-239.
5. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley P, Liotta LA, Israel M (eds), The molecular basis of cancer. Philadelphia: WB Saunders, 1995. p 206-232.
6. Battegy EJ. Angiogenesis: Mechanistic insights, neovascular diseases and therapeutic prospects. J Mol Med 1995;73:333-346.
7. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is secreted angiogenic mitogen. Science 1989;246:1306-1309.
8. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-137.
9. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-6274.
10. Goldfarb M. The fibroblast growth factor family. Cell Growth Differ 1990;1:439-445.
11. Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGF/VPS and its receptors: Role in tumor angiogenesis. Breast Cancer Res Treat 1995;36:139-155.
12. Waltenberger J, Claesso-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and FLT1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
13. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1990;8:519-524.
14. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-898.
15. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1991;255:989-991.
16. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 1994;9:3545-3555.
17. Borg JP, deLapeyriere O, Noguchi T, Rottapel R, Dubreuil P, Birnbaum D. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene 1995;10:973-984.
18. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 187:1579-1586.
19. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846.
20. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993;91:2235-2243.
21. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992; 89:244-253.
22. Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and FLT tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994;9:2683-2690.
23. Hewett PW, Clifford-Murray J. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 1996;221:697-702.
24. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997;76:245-255.
25. Maru Y, Yamaguchi S, Shibuya M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene 1998;16:2585-2595.
26. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-328.
27. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745.
28. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatly GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-761.
29. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Cancer Res 1996;56:2013-2016.
30. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;145:401-409.
31. Chodak GW, Haudenschild C, Gittes RF, Folkman J. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg 1980;192:762-771.
32. Takahashi T, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
33. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
34. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-804.
35. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
36. Banerjee SK, Sarkar DK, Weston AP, De A, Campbell DR. Overexpression of vascular endothelial growth factor and its receptors during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997;18:1155-1161.
37. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
38. Christifori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-1770.
39. Smith-McCune K, Zhu Y-H, Hanahan D, Arbeit J. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 1997;57:1294-1300.
40. Monnaci WT, Merrill MT, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993;264:C994-C1002.
41. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. J Clin Invest 1995;95:1798-1807.
42. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoural microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-934.
43. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small-cell lung carcinomas. Int J Oncol 1995;5:1059-1062.
44. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-1416.
45. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Frequent expression of the vascular endothelial growth factor in human non-small cell lung cancers. Jpn J Clin Oncol 1998;27:176-181.
46. Konishi Y, Kondo H, Denda A, Takahashi S, Inui S. Lung carcinomas induced by oral administration of N-bis(2-hydroxypropyl)nitrosoamine in rats. In: Severi L (ed), Tumors of early life in man and animals, Perugia Quadrennial International Conference of Cancer, Division of Cancer Research, Perugia University, Perugia, Italy, 1978. p 637-649.
47. Kitada H, Tsutsumi M, Tsujiuchi T, et al. Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinog 1996;15:276-283.
48. Honoki K, Tsutsumi M, Miyauchi Y, et al. Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA is associated with spontaneous lung metastasis in rat-transplantable osteosarcoma. Cancer Res 1993;53:5038-5042.
49. Nakae D, Kobayashi Y, Akai H, et al. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res 1997;57:1281-1287.
50. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979;122:166-174.
51. Waltenberger J, Claesson-Welsh L, Siegbahn A, Heldin C-H. Functional comparison of KDR and Flt receptors for the vascular endothelial growth factor. J Cell Biochem (Suppl) 1994; 18A:322
52. Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J Biol Chem 1996;271:17629-17634.
53. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am J Pathol 1997;151:1417-1423.
54. Nicosia RF, Lin YJ, Hazelton D, Qian X. Endogenous regulation of angiogenesis in the rat aorta model. Am J Pathol 1997; 151:1379-1386.
55. Salven P, Mäenpää H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997;33:647-651.
56. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/ VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998;17:303-311.
57. Larcher F, Robles AI, Duran H, et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996; 56:5391-5396.
58. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
59. Takanami I, Tanaka F, Hashizume T, Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res 1997;17:2811-2814.
60. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580.
61. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.